On September 14, 2021 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance’s Emerging Immunotherapeutics for Ovarian Cancer Symposium on September 23, 2021 (Press release, Anixa Biosciences, SEP 14, 2021, View Source [SID1234587671]). Dr. Conejo-Garcia will discuss a number of treatment approaches to ovarian cancer including the Chimeric Antigen Receptor-T cell (CAR-T) Technology approach he invented that is in development with Anixa, known as Follicle Stimulated Hormone Receptor (FSHR)-mediated CAR-T technology ("the technology"). The therapy based on this technology was recently authorized by the U.S. Food and Drug Administration (FDA) for Phase 1 clinical testing.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the presentation, titled, "Tumor-derived antibodies for multi-faceted immunotherapeutic targeting of human ovarian cancer," Dr. Conejo-Garcia will discuss the technology, which is an autologous cell therapy comprised of engineered T-cells that target the follicle stimulating hormone receptor (FSHR). FSHR is found at immunologically relevant levels exclusively on the granulosa cells of the ovaries. Since the target is a hormone receptor, and the target-binding domain is derived from its natural ligand, this technology is also known as CER-T (Chimeric Endocrine Receptor T-cell) therapy, a new type of CAR-T.
"I am particularly motivated to discuss our novel FSHR-mediated CAR-T technology at this event as part of the goal to spread awareness around current and emerging antibody and immune therapies for the treatment of ovarian cancer," commented Dr. Conejo-Garcia. "Moffitt has been in collaboration with Anixa to prioritize and advance this program into human clinical trials. We will look forward to verifying results of this therapeutic approach in solid tumors. Importantly, if this therapeutic approach is successful this could enable a significant shift in the overall treatment paradigm."
Dr. José Conejo-Garcia and his research team developed the FSHR-mediated CAR-T technology when he was at the Wistar Institute where he contributed to report for the first time on the role of T-cell responses in the outcome of ovarian cancer patients. Anixa has an exclusive, world-wide license to this technology.
More information about the event can be found at: View Source